Vous avez cherché: dmards (Anglais - Maltais)

+/- dmards n=167
+/- dmards

switching between biological dmards
meta jsir qlib bejn dmards bijoloġiċi

dose modify concomitant dmards if appropriate.
jekk xieraq biddel id-doża ta’ dmards li qed jingħataw fl-istess waqt.

concurrent administration of biologic dmards or tnf-antagonists
l-għoti flimkien ta’ dmards bijoloġiċi jew antagonisti ta’ tnf

otezla may be used alone or combined with other dmards.
otezla jista’ jintuża waħdu jew flimkien ma’ dmards oħrajn.

concomitant/sequential use of other dmards in rheumatoid arthritis
użu konkomitanti/sekwenzjali ta’ dmards oħra f’artrite rewmatika

there is no experience with cimzia in combination with dmards other than mtx.
m’hemmx esperjenza b’cimzia flimkien ma dmards minbarra mtx.

concomitant treatment with biologic dmards, including tnf blockers, was not allowed.
kura fl-istess ħin b’dmards bijoloġiċi, li tinkludi imblokkaturi ta’ tnf, ma kinitx permessa.

approximately 20% of patients had received prior treatment with dmards other than mtx.
madwar 20% tal-pazjenti kienu rċevew kura minn qabel b’dmards oħra mhux mtx.

benefit was seen both in patients taking otezla alone and those also taking other dmards.
il-benefiċċju deher kemm fil- pazjenti li kienu qed jieħdu otezla waħdu kif ukoll f’dawk li kienu qed jieħdu dmards oħrajn.

patients also had active psoriatic skin lesions or a documented history of psoriasis and had failed 1 or more dmards.
il-pazjenti kellhom ukoll leżjonijiet tal-ġilda psorijatiċi attivi jew storja dokumentata ta’ psorijażi u li m’għaddewx dmard 1 jew iżjed.

concomitant administration of hepatotoxic or haematotoxic dmards (e.g. methotrexate) is not advisable.
it-teħid flimkien ta’ mediċini tal-klassitad-dmard li huma tossiċi għall-fwied u għad-demm (e.g. methotrexate) mhux irrakkomandat.

patients receiving concomitant nsaids and conventional dmards were 72.6% and 70.2% respectively.
il-pazjenti li ħadu f’istess ħin nsaids u dmards konvenzjonali kienu 72.6% u 70.2% rispettivament.

in study iv, tocilizumab was administered intravenously every 4 weeks in combination with other dmards vs. placebo and other dmards.
fi studju iv, tocilizumab ingħata minn ġol-vina kull erba’ ġimgħat flimkien ma’ dmards oħra kontra plaċebo u dmards oħra.

the long-term open label extension studies included 2,562 patients who received tocilizumab 8 mg/ kg with or without dmards.
l- istudji ta ’ estensjoni open label fit- tul inkludew 2, 562 pazjent li irċevew tocilizumab 8 mg/ kg flimkien ma ’ jew mingħajr dmards.

decreases below 0.5 x 109/ l were reported in 0.3% patients receiving tocilizumab 8 mg/kg plus dmards.
tnaqqis taħt 0.5 x 109/ l ġie rrapportat f’0.3 % tal-pazjenti li rċevew tocilizumab 8 mg/kg flimkien ma’ dmards.

patients had previously been treated with nsaids (86%), dmards (80%), and corticosteroids (24%).
il-pazjenti kienu kkurati qabel b’nsaids (86%), dmards (80%), u kortikosterojdi (24%).

apremilast was used as a monotherapy (34.8%) or in combination with stable doses of small molecule dmards (65.2%).
apremilast intuża bħala monoterapija (34.8%) jew flimkien ma’ dożi stabbli ta’ dmards ta’ molekuli żgħar (65.2%).

psa study ii with 12 -week duration, treated 100 patients who had an inadequate response to dmard therapy.
studju psa ii li dam 12 -il ġimgħa, tratta 100 pazjent li kellhom rispons mhux adegwat għat-terapija dmard.